drugset / Trial / NCT04074551

A Phase 3 Study to Compare the Efficacy and Safety of Co-administered HGP0608, HGP0904 and HCP1306 Versus HCP1701 in Patients With Hypertension and Dyslipidemia

NCT04074551

Phase 3 Completed 145 enrolled Hanmi Pharmaceutical Company Limited
RandomizedParallel-groupDouble-blindTreatment

Summary

A Randomized, Double-blinded, Multi-center, Phase III Study to Compare The Efficacy and Safety of Co-administered HGP0608, HGP0904 and HCP1306 versus HCP1701 in Patients with Hypertension and Dyslipidemia

Timeline

Start
2019-07-16
Primary completion
2020-03-17
Completion
2020-03-17

Drugs

EvaluationDrugModalityDoseRoute
Comparator Amlodipine Other / unclassified 5 mg
Comparator Ezetimibe Unknown 10 mg
Subject HCP1701 Unknown
Comparator Losartan Other / unclassified 100 mg
Comparator Rosuvastatin Small molecule 20 mg